Vitamin D2-enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPswe/PS1dE9 transgenic mice

PLoS One. 2013 Oct 18;8(10):e76362. doi: 10.1371/journal.pone.0076362. eCollection 2013.

Abstract

Vitamin D deficiency is widespread, affecting over 30% of adult Australians, and increasing up to 80% for at-risk groups including the elderly (age>65). The role for Vitamin D in development of the central nervous system is supported by the association between Vitamin D deficiency and incidence of neurological and psychiatric disorders including Alzheimer's disease (AD). A reported positive relationship between Vitamin D status and cognitive performance suggests that restoring Vitamin D status might provide a cognitive benefit to those with Vitamin D deficiency. Mushrooms are a rich source of ergosterol, which can be converted to Vitamin D2 by treatment with UV light, presenting a new and convenient dietary source of Vitamin D2. We hypothesised that Vitamin D2-enriched mushrooms (VDM) could prevent the cognitive and pathological abnormalities associated with dementia. Two month old wild type (B6C3) and AD transgenic (APPSwe/PS1dE9) mice were fed a diet either deficient in Vitamin D2 or a diet which was supplemented with VDM, containing 1±0.2 µg/kg (∼54 IU/kg) vitamin D2, for 7 months. Effects of the dietary intervention on memory were assessed pre- and post-feeding. Brain sections were evaluated for amyloid β (Aβ) plaque loads and inflammation biomarkers using immuno-histochemical methods. Plasma vitamin D metabolites, Aβ40, Aβ42, calcium, protein and cholesterol were measured using biochemical assays. Compared with mice on the control diet, VDM-fed wild type and AD transgenic mice displayed improved learning and memory, had significantly reduced amyloid plaque load and glial fibrillary acidic protein, and elevated interleukin-10 in the brain. The results suggest that VDM might provide a dietary source of Vitamin D2 and other bioactives for preventing memory-impairment in dementia. This study supports the need for a randomised clinical trial to determine whether or not VDM consumption can benefit cognitive performance in the wider population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agaricus / chemistry*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / blood
  • Amyloid beta-Peptides / metabolism
  • Animal Feed
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Calcium / blood
  • Cholesterol / blood
  • Cytokines / metabolism
  • Dietary Supplements
  • Disease Models, Animal
  • Ergocalciferols / chemistry
  • Ergocalciferols / pharmacology*
  • Ergocalciferols / toxicity
  • Inflammation / metabolism
  • Inflammation Mediators / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Maze Learning
  • Memory / drug effects*
  • Mice
  • Mice, Transgenic
  • Plaque, Amyloid
  • Time Factors
  • Vitamin D / blood
  • Vitamin D / metabolism

Substances

  • Amyloid beta-Peptides
  • Cytokines
  • Ergocalciferols
  • Inflammation Mediators
  • Vitamin D
  • Cholesterol
  • Calcium

Grants and funding

This work was conducted with support from Horticulture Australia Limited, the Australian Mushroom Growers Association, the Australian Government and the CSIRO Preventative Health National Research Flagship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.